Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

ANB032

Other · developed by AnaptysBio

Phase 2 Most advanced trial (none active)
ANAB Developer
1 Registered trials

What is ANB032?

ANB032 is an investigational drug studied in Atopic Dermatitis Eczema.

At a glance

Drug type
Other
Therapy area
Dermatology
Developer
AnaptysBio, Inc. (ANAB)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05935085 Phase 2 Atopic Dermatitis Eczema Terminated ANAB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Atopic Dermatitis Eczema

More from AnaptysBio

Etokimab Phase 2 Rosnilimab Phase 2

Follow ANAB, the company behind ANB032

See ANAB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ANAB catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.